Ifm_05-may 2022 Site

A significant number of patients (roughly 27%) had to stop the maintenance therapy early due to adverse side effects.

Due to the risk of secondary cancers identified in the IFM-05 trial, long-term monitoring for new symptoms or blood changes is standard practice for those on this regimen. IFM_05-May 2022

Patients are encouraged to discuss the balance between disease control and the toxic long-term effects of maintenance drugs with their oncology team. A significant number of patients (roughly 27%) had

If you are looking for guidance based on this study's results: IFM_05-May 2022

To determine if continuous low-dose chemotherapy after a transplant could improve overall survival and keep the disease controlled for longer periods.

Lenalidomide was the primary drug used for maintenance in this study. Key Findings: